Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


  • 123456 Profile photo of Madelyn

    This multicenter study enrolled 60 consecutive CLL patients >=80 who were treated with ibrutinib to assess safety and efficacy in the elderly patient population. 5% were on anticoagulants at baseline and 35% on antiplatelet. With a median f/u of 27 months, 15% developed atrial fibrillation, 33% developed infections, and 36% had a bleeding event.